Tristel Regulatory News (TSTL)

Tristel plc

("Tristel" or "the Company")

Trading Update and notice of results

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products provides a trading update for the six months ended 31 December 2013, ahead of previously upgraded expectations.

Tristel addresses three distinct markets: Human Healthcare, Animal Healthcare and Contamination Control, with three distinctively branded product ranges: Tristel, Anistel and Crystel.

Tristel has had a strong first half and expects to report encouraging performances from all business segments. Furthermore, following a better than expected December, revenue will be in excess of £6.4m (2012 £4.4m) and pre-tax profit in excess of £0.7m (2012 adjusted pre-tax loss of £0.6m) exceeding levels indicated in the AGM trading update issued in December. The Company has benefited from strong operational cashflow in the first half of the year and net cash at 31 December was £1.4m (2012 net debt of £0.4m).

Tristel will announce its half year results on 3 March 2014.

Paul Swinney, Chief Executive Officer, comments: "We are delighted with the progress made in the first half of this financial year, in particular the growth seen in sales of Tristel's products used to disinfect non & single lumened instruments, hospital surfaces and within aseptic units. We continue to build upon these successes with confidence that they will continue into the second half and beyond." 

For further information please contact: